Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.

Moderna’s ( NASDAQ: MRNA) steep fall on Friday after President-elect Donald Trump selected vaccine critic Robert F. Kennedy Jr. to head the U.S. Department of Health and Human Services makes a good ...

Shares of vaccine makers such as Moderna (MRNA) and Pfizer (PFE) have plunged on news that president-elect Donald Trump has ...

Shares in biotech firm Moderna (NASDAQ: MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to ...

Shares started out the week mixed in Asia after U.S. stocks fell to their worst loss since Election Day. Japan’s Nikkei 225 index dropped 1% to 38,255.65 as the yen regained some strength against the ...

Moderna reported phase 3 results with its vaccine last month. Meanwhile, for CureVac, the deal provides a much-needed cash injection, coming alongside an announcement that it will slash its ...

HSBC upgraded Moderna (MRNA) to Hold from Reduce with a $58 price target Don't Miss our Black Friday Offers:Discover the latest stocks ...

Piper Sandler lowered the firm’s price target on Moderna (MRNA) to $69 from $115 and keeps an Overweight rating on the shares. The firm notes ...

The Conservative leader said he will work to bring foreign investment and industry back to Canada with policies similar to Trump's vows to slash taxes and regulations.

Veteran broadcaster Alan Jones has been charged with historical indecent assault and sexual touching offences spanning two decades.

Why the iPhone SE 4 Could Be One of Apple's Most Important Products of 2025 ...